Cargando…
Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis
We investigated the association between early tumor shrinkage (ETS) and treatment outcome in patients with hepatocellular carcinoma treated with lenvatinib (LEN). A retrospective analysis was performed in 104 patients. ETS was defined as tumor shrinkage at the first evaluation in the sum of target l...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140019/ https://www.ncbi.nlm.nih.gov/pubmed/32209994 http://dx.doi.org/10.3390/cancers12030754 |
_version_ | 1783518900699267072 |
---|---|
author | Takahashi, Aya Moriguchi, Michihisa Seko, Yuya Shima, Toshihide Mitsumoto, Yasuhide Takashima, Hidetaka Kimura, Hiroyuki Fujii, Hideki Ishikawa, Hiroki Yo, Takaharu Ishiba, Hiroshi Morita, Atsuhiro Jo, Masayasu Nagao, Yasuyuki Arai, Masahiro Hara, Tasuku Okajima, Akira Muramatsu, Akira Yoshinami, Naomi Nakajima, Tomoki Mitsuyoshi, Hironori Umemura, Atsushi Nishikawa, Taichiro Yamaguchi, Kanji Okanoue, Takeshi Itoh, Yoshito |
author_facet | Takahashi, Aya Moriguchi, Michihisa Seko, Yuya Shima, Toshihide Mitsumoto, Yasuhide Takashima, Hidetaka Kimura, Hiroyuki Fujii, Hideki Ishikawa, Hiroki Yo, Takaharu Ishiba, Hiroshi Morita, Atsuhiro Jo, Masayasu Nagao, Yasuyuki Arai, Masahiro Hara, Tasuku Okajima, Akira Muramatsu, Akira Yoshinami, Naomi Nakajima, Tomoki Mitsuyoshi, Hironori Umemura, Atsushi Nishikawa, Taichiro Yamaguchi, Kanji Okanoue, Takeshi Itoh, Yoshito |
author_sort | Takahashi, Aya |
collection | PubMed |
description | We investigated the association between early tumor shrinkage (ETS) and treatment outcome in patients with hepatocellular carcinoma treated with lenvatinib (LEN). A retrospective analysis was performed in 104 patients. ETS was defined as tumor shrinkage at the first evaluation in the sum of target lesions’ longest diameters from baseline according to the Response Evaluation Criteria in Solid Tumors (RECIST). The median overall survival (OS) was not reached, whereas the median progression-free survival (PFS) was 5.0 months. The receiver operating characteristic curve analysis in differentiating long-term responders (PFS ≥ 5.0 months) from short-term responders (PFS < 5.0 months) revealed an ETS cut-off value of 10%. ETS ≥ 10% was significantly correlated with better PFS and OS compared with ETS < 10%. Additionally, ETS ≥ 10% showed a better discrimination ability on prognosis compared with modified RECIST-based objective response at the first evaluation. Multivariate analysis confirmed ETS ≥ 10% as an independent predictor of better OS, as well as a Child–Pugh score of 5 and macrovascular invasion. In conclusion, ETS ≥ 10% was strongly associated with outcome in patients treated with LEN. This biomarker could allow earlier assessment of the treatment response and guide treatment decision-making for HCC. |
format | Online Article Text |
id | pubmed-7140019 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71400192020-04-13 Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis Takahashi, Aya Moriguchi, Michihisa Seko, Yuya Shima, Toshihide Mitsumoto, Yasuhide Takashima, Hidetaka Kimura, Hiroyuki Fujii, Hideki Ishikawa, Hiroki Yo, Takaharu Ishiba, Hiroshi Morita, Atsuhiro Jo, Masayasu Nagao, Yasuyuki Arai, Masahiro Hara, Tasuku Okajima, Akira Muramatsu, Akira Yoshinami, Naomi Nakajima, Tomoki Mitsuyoshi, Hironori Umemura, Atsushi Nishikawa, Taichiro Yamaguchi, Kanji Okanoue, Takeshi Itoh, Yoshito Cancers (Basel) Article We investigated the association between early tumor shrinkage (ETS) and treatment outcome in patients with hepatocellular carcinoma treated with lenvatinib (LEN). A retrospective analysis was performed in 104 patients. ETS was defined as tumor shrinkage at the first evaluation in the sum of target lesions’ longest diameters from baseline according to the Response Evaluation Criteria in Solid Tumors (RECIST). The median overall survival (OS) was not reached, whereas the median progression-free survival (PFS) was 5.0 months. The receiver operating characteristic curve analysis in differentiating long-term responders (PFS ≥ 5.0 months) from short-term responders (PFS < 5.0 months) revealed an ETS cut-off value of 10%. ETS ≥ 10% was significantly correlated with better PFS and OS compared with ETS < 10%. Additionally, ETS ≥ 10% showed a better discrimination ability on prognosis compared with modified RECIST-based objective response at the first evaluation. Multivariate analysis confirmed ETS ≥ 10% as an independent predictor of better OS, as well as a Child–Pugh score of 5 and macrovascular invasion. In conclusion, ETS ≥ 10% was strongly associated with outcome in patients treated with LEN. This biomarker could allow earlier assessment of the treatment response and guide treatment decision-making for HCC. MDPI 2020-03-23 /pmc/articles/PMC7140019/ /pubmed/32209994 http://dx.doi.org/10.3390/cancers12030754 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Takahashi, Aya Moriguchi, Michihisa Seko, Yuya Shima, Toshihide Mitsumoto, Yasuhide Takashima, Hidetaka Kimura, Hiroyuki Fujii, Hideki Ishikawa, Hiroki Yo, Takaharu Ishiba, Hiroshi Morita, Atsuhiro Jo, Masayasu Nagao, Yasuyuki Arai, Masahiro Hara, Tasuku Okajima, Akira Muramatsu, Akira Yoshinami, Naomi Nakajima, Tomoki Mitsuyoshi, Hironori Umemura, Atsushi Nishikawa, Taichiro Yamaguchi, Kanji Okanoue, Takeshi Itoh, Yoshito Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis |
title | Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis |
title_full | Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis |
title_fullStr | Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis |
title_full_unstemmed | Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis |
title_short | Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis |
title_sort | early tumor shrinkage as a predictive factor for outcomes in hepatocellular carcinoma patients treated with lenvatinib: a multicenter analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140019/ https://www.ncbi.nlm.nih.gov/pubmed/32209994 http://dx.doi.org/10.3390/cancers12030754 |
work_keys_str_mv | AT takahashiaya earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT moriguchimichihisa earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT sekoyuya earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT shimatoshihide earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT mitsumotoyasuhide earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT takashimahidetaka earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT kimurahiroyuki earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT fujiihideki earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT ishikawahiroki earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT yotakaharu earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT ishibahiroshi earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT moritaatsuhiro earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT jomasayasu earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT nagaoyasuyuki earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT araimasahiro earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT haratasuku earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT okajimaakira earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT muramatsuakira earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT yoshinaminaomi earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT nakajimatomoki earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT mitsuyoshihironori earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT umemuraatsushi earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT nishikawataichiro earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT yamaguchikanji earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT okanouetakeshi earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis AT itohyoshito earlytumorshrinkageasapredictivefactorforoutcomesinhepatocellularcarcinomapatientstreatedwithlenvatinibamulticenteranalysis |